In silico risk assessment for drug-induction of cardiac arrhythmia

Progress in Biophysics and Molecular Biology

Volumn 98, Issue 1, 2008, Pages 52-60

  Suzuki, Shingo ^a   Murakami, Shingo ^a,b   Tsujimae, Kenji ^a   Findlay, Ian ^c   Kurachi, Yoshihisa ^a,b  

^a OSAKA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^b OSAKA UNIVERSITY   (Japan)

^c UNIVERSITÉ DE TOURS   (France)

Author keywords

Cardiac action potential; Cardiac arrhythmia; IKr blocker; Mapping

Indexed keywords

ANTIARRHYTHMIC AGENT; POTASSIUM CHANNEL BLOCKING AGENT;

ACTION POTENTIAL; ANIMAL; BIOLOGY; BIOPHYSICS; CHEMICALLY INDUCED DISORDER; COMPUTER PROGRAM; DRUG EFFECT; HEART ARRHYTHMIA; HEART VENTRICLE; HUMAN; METABOLISM; METHODOLOGY; PATHOLOGY; PHENOTYPE; REVIEW; RISK; RISK ASSESSMENT; TORSADE DES POINTES;

ACTION POTENTIALS; ANIMALS; ANTI-ARRHYTHMIA AGENTS; ARRHYTHMIAS, CARDIAC; BIOPHYSICS; COMPUTATIONAL BIOLOGY; HEART VENTRICLES; HUMANS; PHENOTYPE; POTASSIUM CHANNEL BLOCKERS; RISK; RISK ASSESSMENT; SOFTWARE; TORSADES DE POINTES;

EID: 50049127535     PISSN: 00796107     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.pbiomolbio.2008.05.003     Document Type: Review

References (42)

1. Aiba T., Shimizu W., Inagaki M., Noda T., Miyoshi S., Ding W.G., Zankov D.P., Toyoda F., Matsuura H., Horie M., and Sunagawa K. Cellular and ionic mechanism for drug-induced long QT syndrome and effectiveness of verapamil. J. Am. Coll. Cardiol. 45 (2005) 300-307
2. Belardinelli L., Antzelevitch C., and Vos M.A. Assessing predictors of drug-induced torsade de pointes. Trends Pharmacol. Sci. 24 (2003) 619-625
3. Courtemanche M., Ramirez R.J., and Nattel S. Ionic targets for drug therapy and atrial fibrillation-induced electrical remodeling: insights from a mathematical model. Cardiovasc. Res. 42 (1999) 477-489
4. i overloaded cardiac myocytes: a simulation study. Biophys. J. 78 (2000) 2392-2404
5. Feldman A.M., Baughman K.L., Lee W.K., Gottlieb S.H., Weiss J.L., Becker L.C., and Strobeck J.E. Usefulness of OPC-8212, a quinolinone derivative, for chronic congestive heart failure in patients with ischemic heart disease or idiopathic dilated cardiomyopathy. Am. J. Cardiol. 68 (1991) 1203-1210
6. Findlay I., Suzuki S., Murakami S., and Kurachi Y. Physiological modulation of voltage-dependent inactivation in the cardiac muscle L-type calcium channel: a modelling study. Prog. Biophys. Mol. Biol. 96 (2008) 482-498
7. Hatem S., Le Grand B., Le Heuzey J.Y., Couetil J.P., and Deroubaix E. Differential effects of quinidine and flecainide on plateau duration of human atrial action potential. Basic Res. Cardiol. 87 (1992) 600-609
8. Hoffmann P., and Warner B. Are hERG channel inhibition and QT interval prolongation all there is in drug-induced torsadogenesis? A review of emerging trends. J. Pharmacol. Toxicol. Methods 53 (2006) 87-105
9. Hondeghem L.M. Frequency dependence of class I and class III antiarrhythmic agents explaining their antiarrhythmic and proarrhythmic properties. In: Franz M.R. (Ed). Monophasic Action Potentials (2000), Futura Publishing, Mount Kisco, NY 381-394
10. Hondeghem L.M. Thorough QT/QTc not so thorough: removes torsadogenic predictors from the T-wave, incriminates safe drugs, and misses profibrillatory drugs. J. Cardiovasc. Electrophysiol. 17 (2006) 337-340
11. Hondeghem L.M. Relative contributions of TRIaD and QT to proarrhythmia. J. Cardiovasc. Electrophysiol. 18 (2007) 655-657
12. Hondeghem L.M., and Hoffmann P. Blinded test in isolated female rabbit heart reliably identifies action potential duration prolongation and proarrhythmic drugs: importance of triangulation, reverse use dependence, and instability. J. Cardiovasc. Pharmacol. 41 (2003) 14-24
13. + current by dofetilide. Circ. Res. 72 (1993) 75-83
14. Kannankeril P.J., and Roden D.M. Drug-induced long QT and torsade de pointes: recent advances. Curr. Opin. Cardiol. 22 (2007) 239-243
15. + channels expressed in a mammalian cell line. J. Pharmacol. Exp. Ther. 294 (2000) 339-346
16. Kuryshev Y.A., Brown A.M., Wang L., Benedict C.R., and Rampe D. Interactions of the 5-hydroxytryptamine 3 antagonist class of antiemetic drugs with human cardiac ion channels. J. Pharmacol. Exp. Ther. 295 (2000) 614-620
17. Lawrence C.L., Pollard C.E., Hammond T.G., and Valentin J.P. Nonclinical proarrhythmia models: predicting torsades de pointes. J. Pharmacol. Toxicol. Methods 52 (2005) 46-59
18. Liu X.K., Katchman A., Ebert S.N., and Woosley R.L. The antiestrogen tamoxifen blocks the delayed rectifier potassium current, IKr, in rabbit ventricular myocytes. J. Pharmacol. Exp. Ther. 287 (1998) 877-883
19. Luo C.H., and Rudy Y. A dynamic model of the cardiac ventricular action potential. I. Simulations of ionic currents and concentration changes. Circ. Res. 74 (1994) 1071-1096
20. Martin C.L., Palomo M.A., and Mcmahon E.G. Comparison of bidisomide, flecainide and dofetilide on action potential duration in isolated canine atria: effect of isoproterenol. J. Pharmacol. Exp. Ther. 278 (1996) 154-162
21. Matsuda T., Takeda K., Ito M., Yamagishi R., Tamura M., Nakamura H., Tsuruoka N., Saito T., Masumiya H., Suzuki T., Iida-Tanaka N., Itokawa-Matsuda M., Yamashita T., Tsuruzoe N., Tanaka H., and Shigenobu K. Atria selective prolongation by NIP-142, an antiarrhythmic agent, of refractory period and action potential duration in guinea pig myocardium. J. Pharmacol. Sci. 98 (2005) 33-40
22. Morganroth J. Relations of QTc prolongation on the electrocardiogram to torsades de pointes: definitions and mechanisms. Am. J. Cardiol. 72 (1993) 10B-13B
23. Noble D., and Noble P.J. Late sodium current in the pathophysiology of cardiovascular disease: consequences of sodium-calcium overload. Heart 92 (2006) iv1-iv5
24. Noble D., and Varghese A. Modeling of sodium-calcium overload arrhythmias and their suppression. Can. J. Cardiol. 14 (1998) 97-100
25. Roden D.M. Drug-induced prolongation of the QT interval. N. Engl. J. Med. 350 (2004) 1013-1022
26. Roden D.M., Iansmith D.H., and Woosley R.L. Frequency-dependent interactions of mexiletine and quinidine on depolarization and repolarization in canine Purkinje fibers. J. Pharmacol. Exp. Ther. 243 (1987) 1218-1224
27. + current. Differential sensitivity to block by class III antiarrhythmic agents. J. Gen. Physiol. 96 (1990) 195-215
28. + current is composed of two currents in guinea pig atrial cells. Am. J. Physiol. 260 (1991) H393-H399
29. Shah R.R., and Hondeghem L.M. Refining detection of drug-induced proarrhythmia: QT interval and TRIaD. Heart Rhythm 2 (2005) 758-772
30. Smith W.M., and Gallagher J.J. "Les torsades de pointes": an unusual ventricular arrhythmia. Ann. Intern. Med. 93 (1980) 578-584
31. Suzuki S., Tsujimae K., Murakami S., Findlay I., and Kurachi Y. Two-dimensional mapping of cardiac action potential duration for assessing the risk of drug-induced arrhythmia. The Proceedings of the 80th Annual Meeting of the Japanese Pharmacological Society, March 14-16, 2007, Nagoya, Japan. Abst. J. Pharmacol. Sci. 103 Suppl. I (2007) 196
32. Taylor D. Ziprasidone in the management of schizophrenia. CNS Drugs 17 (2003) 423-430
33. Torp-Pedersen C., Brendorp B., and Kober L. Dofetilide: a class III anti-arrhythmic drug for the treatment of atrial fibrillation. Expert. Opin. Investig. Drugs 9 (2000) 2695-2704
34. + current. Circulation 96 (1997) 3696-3703
35. Tsujimae K., Suzuki S., Yamada M., and Kurachi Y. Comparison of kinetic properties of quinidine and dofetilide block of HERG channels. Eur. J. Pharmacol. 493 (2004) 29-40
36. Van Opstal J.M., Schoenmakers M., Verduyn S.C., de Groot S.H., Leunissen J.D., van Der Hulst F.F., Molenschot M.M., Wellens H.J., and Vos M.A. Chronic amiodarone evokes no torsade de pointes arrhythmias despite QT lengthening in an animal model of acquired long-QT syndrome. Circulation 104 (2001) 2722-2727
37. Viswanathan P.C., and Rudy Y. Pause induced early afterdepolarizations in the long QT syndrome: a simulation study. Cardiovasc. Res. 42 (1999) 530-542
38. Ks heterogeneity on action potential duration and its rate dependence: a simulation study. Circulation 99 (1999) 2466-2474
39. Wang S., Liu S., Morales M.J., Strauss H.C., and Rasmusson R.L. A quantitative analysis of the activation and inactivation kinetics of HERG expressed in Xenopus oocytes. J. Physiol. 502 (1997) 45-60
40. Warner B., and Hoffmann P. Investigation of the potential of clozapine to cause torsade de pointes. Adverse Drug React. Toxicol. Rev. 21 (2002) 189-203
41. Yan G.X., and Antzelevitch C. Cellular basis for the normal T wave and the electrocardiographic manifestations of the long-QT syndrome. Circulation 98 (1998) 1928-1936
42. + current in ventricular myocytes of the guinea-pig type. Theoretical formulation and their role in repolarization. Circ. Res. 77 (1995) 140-152